Paper Details

  1. Home
  2. Paper Details

Effects of ferric citrate and intravenous iron sucrose on markers of mineral, bone, and iron homeostasis in a rat model of CKD-MBD.

Author: AllenMatthew R, AvinKeith G, BirueteAnnabel, ChenNeal X, ClinkenbeardErica L, MetzgerCorinne E, MoeSharon M, O'NeillKalisha, SrinivasanShruthi, StacyAlexander J, SwallowElizabeth A, VrabecCurtis

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
Research Support, U.S. Gov't, Non-P.H.S.Research funding provided by US government agencies other than the Public Health Service.
Research Support, N.I.H., ExtramuralResearch funding provided by the NIH to external research institutions and researchers.

Overview

Oral ferric citrate (FC) improved phosphorus homeostasis, some iron-related parameters, and the production and cleavage of FGF23 in rats with moderate chronic kidney disease (CKD). IV iron sucrose equally reduced aorta and heart calcifications but had a different effect on bone.
Paper Details　
Original Abstract of the Article :
BACKGROUND: Anemia and chronic kidney disease-mineral and bone disorder (CKD-MBD) are common and begin early in CKD. Limited studies have concurrently compared the effects of ferric citrate (FC) versus intravenous (IV) iron on CKD-MBD and iron homeostasis in moderate CKD. METHODS: We tested the eff...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9494145/

データ提供：米国国立医学図書館（NLM）

Ferric Citrate and Intravenous Iron Sucrose: Navigating the Complex Landscape of CKD-MBD

Chronic kidney disease-mineral and bone disorder (CKD-MBD) is a complex condition that can develop in people with chronic kidney disease. It's like a desert ecosystem, with many interconnected factors that can contribute to bone health problems. This study explores the effects of two different iron treatments, ferric citrate (FC) and intravenous iron sucrose, on CKD-MBD in rats with moderate kidney disease. The researchers examined a range of markers related to mineral homeostasis, bone health, and iron metabolism. Their findings offer valuable insights into the potential benefits and drawbacks of these two iron treatments. They found that FC was more effective than intravenous iron sucrose in improving phosphorus homeostasis, a key factor in CKD-MBD. However, intravenous iron sucrose was associated with better bone mechanical properties. This suggests that the best treatment option for CKD-MBD may depend on the specific needs of the individual patient. The study highlights the importance of a personalized approach to managing CKD-MBD, taking into account the unique characteristics of each patient.

A Tailored Approach to Managing CKD-MBD

This study highlights the need for a tailored approach to managing CKD-MBD. The optimal treatment option may depend on the specific needs of the individual patient, taking into account their mineral balance, bone health, and iron status.

Improving Bone Health in CKD

This study underscores the importance of managing bone health in patients with CKD. The findings suggest that both FC and intravenous iron sucrose can have positive effects on bone health, but the optimal treatment option may vary depending on the individual patient.

Dr.Camel's Conclusion

This study is a journey through the complex desert of CKD-MBD. It highlights the importance of managing both mineral homeostasis and bone health in patients with this condition. The findings suggest that the optimal treatment option may depend on the specific needs of the individual patient. By understanding the unique characteristics of each patient, we can navigate this challenging landscape with greater confidence and provide them with the best possible care.

Date :
  1. Date Completed 2022-09-23
  2. Date Revised 2023-04-29
Further Info :

Pubmed ID

35482713

DOI: Digital Object Identifier

PMC9494145

Related Literature

Article Analysis
・Effects of ferric citrate
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.